Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 1
1990 1
1991 2
1992 3
1993 2
1994 4
1996 1
1997 1
1998 6
1999 2
2000 8
2001 6
2002 9
2003 9
2004 10
2005 13
2006 14
2007 9
2008 14
2009 17
2010 14
2011 15
2012 10
2013 10
2014 20
2015 19
2016 18
2017 28
2018 23
2019 30
2020 19
2021 20
2022 23
2023 15
2024 16

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

351 results

Results by year

Filters applied: . Clear all
Page 1
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L; ECHELON-2 Study Group. Horwitz S, et al. Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4. Lancet. 2019. PMID: 30522922 Free PMC article. Clinical Trial.
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators. Kim YH, et al. Among authors: porcu p. Lancet Oncol. 2018 Sep;19(9):1192-1204. doi: 10.1016/S1470-2045(18)30379-6. Epub 2018 Aug 9. Lancet Oncol. 2018. PMID: 30100375 Free article. Clinical Trial.
Non-Hodgkin's lymphomas.
Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wierda WG, Yahalom J, Zafar N. Zelenetz AD, et al. Among authors: porcu p. J Natl Compr Canc Netw. 2011 May;9(5):484-560. doi: 10.6004/jnccn.2011.0046. J Natl Compr Canc Netw. 2011. PMID: 21550968 No abstract available.
Non-Hodgkin's lymphomas.
Zelenetz AD, Advani RH, Byrd JC, Czuczman MS, Damon LE, Duvic M, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Nademanee A, Olsen EA, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J, Yunus F; National Comprehensive Cancer Network. Zelenetz AD, et al. Among authors: porcu p. J Natl Compr Canc Netw. 2008 Apr;6(4):356-421. doi: 10.6004/jnccn.2008.0030. J Natl Compr Canc Netw. 2008. PMID: 18433606 No abstract available.
Sézary Syndrome: Clinical and Biological Aspects.
Kohnken R, Fabbro S, Hastings J, Porcu P, Mishra A. Kohnken R, et al. Among authors: porcu p. Curr Hematol Malig Rep. 2016 Dec;11(6):468-479. doi: 10.1007/s11899-016-0351-0. Curr Hematol Malig Rep. 2016. PMID: 27704468 Review.
AIDS-associated malignancies.
Shah MH, Porcu P, Mallery SR, Caligiuri MA. Shah MH, et al. Among authors: porcu p. Cancer Chemother Biol Response Modif. 2003;21:717-46. doi: 10.1016/s0921-4410(03)21034-6. Cancer Chemother Biol Response Modif. 2003. PMID: 15338771 Review. No abstract available.
Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study.
Haverkos B, Alpdogan O, Baiocchi R, Brammer JE, Feldman TA, Capra M, Brem EA, Nair S, Scheinberg P, Pereira J, Shune L, Joffe E, Young P, Spruill S, Katkov A, McRae R, Royston I, Faller DV, Rojkjaer L, Porcu P. Haverkos B, et al. Among authors: porcu p. Blood Adv. 2023 Oct 24;7(20):6339-6350. doi: 10.1182/bloodadvances.2023010330. Blood Adv. 2023. PMID: 37530631 Free PMC article. Clinical Trial.
Prediction of chronic lung allograft dysfunction: a systems medicine challenge.
Pison C, Magnan A, Botturi K, Sève M, Brouard S, Marsland BJ, Ernst F, Paprotka T, Deplanche K, Fritz A, Siroux V, Boissel JP, Corris PA, Auffray C, Nicod LP; SysCLAD consortium. Pison C, et al. Eur Respir J. 2014 Mar;43(3):689-93. doi: 10.1183/09031936.00161313. Eur Respir J. 2014. PMID: 24585866 Free article. No abstract available.
351 results